1,000 Studies Later: 10 Things I Learned about Health

Key wellness strategies, self-care techniques, and productivity-adjacent takeaways

Use resistant starch to target visceral fat

• Goal: Reduce visceral fat (fat around organs).
• Evidence (high level): Multiple randomized controlled trials showed reduced visceral fat (e.g., MRI changes).
• Practical dosing tip:
  • Studies used ~40 g/day of resistant starch.
  • Powder products may require more than 40 g of powder to reach 40 g of actual resistant starch.
• How to implement: Add resistant starch powder to a smoothie (reported to not change taste much and improves consistency).
• Food caveat: Natural sources (e.g., green banana, plantain) may not reliably reach the study dose.

Consider GLP-1 receptor agonist–type peptides for benefits beyond fat loss (medical discussion)

• Potential extra benefits mentioned:
  • Osteoarthritis (cartilage/joint “rejuvenation” in a small clinical trial)
  • Liver health
• Mechanism nuance: Benefits may be partly independent of weight/fat loss and may involve shared pathways.
• Example peptide discussed: Retatrutide
  • Key idea: May help preserve metabolic rate during weight loss (one reason weight loss can become harder later).
• Caution: Possible gastrointestinal side effects.

Add omega-3 fats to support muscle strength

• Goal: Small improvement in muscle strength.
• Note: Some evidence suggests effects may occur even without exercise (exercise could still enhance benefits).
• Dosing used across trials: ~1.4–1.5 g/day combined DHA + EPA.
• How to implement: Fish oil, krill oil, or equivalent DHA/EPA formulations.

Choose protein strategies that increase satiety (leucine focus)

• Concept: A brain “protein sensing” mechanism (CaV3.1) may increase satiety by responding to an amino acid involved in protein.
• Practical takeaway: Prefer leucine-rich protein sources to strengthen the satiety signal and reduce hunger/food intake.

Creatine for depression—possible only in specific groups (early evidence)

• Mixed evidence: Some randomized trials show no benefit; others show improvement.
• Possible responder profile: People with clinically diagnosed depression, potentially especially if on SSRIs.
• Microbiome angle: One study suggests depression may impair creatine absorption; combining microbiome support + creatine improved depression severity (HAM-D).
• Caution: Evidence is promising but immature (needs larger trials and cleaner study arms).

Vitamin K2 (MK4) as an adjunct signal in liver cancer (with strong safety caution)

• Evidence described: A meta-analysis and deeper look into included studies suggested vitamin K2 (MK4) paired with conventional therapies may slow liver cancer progression (hepatocellular carcinoma).
• Important dosing clarification:
  • Liver-cancer research used MK4 in milligram (mg) doses (example reported: 45 mg).
  • Cardiovascular research often focuses on MK7 in microgram (mcg) doses—not the same.
• Safety note: Vitamin K2 interacts with the blood/clotting cascade, so it should be handled cautiously and not taken as generic advice.

Microbiome “anti-cancer” effects—supporting options now mostly indirect

• Claimed evidence: Early-phase studies using microbiome modification (described as a fecal transplant “pill”) reported strong survival improvements across multiple cancer types.
• Practical implication: Since “health poop pills” aren’t broadly available, the speaker highlights:
  • Prebiotics / dietary fiber as a current, accessible way to support the microbiome.
• Takeaway: Early clinical data suggests microbiome improvement could have major impacts, but more research is needed.

Drink caffeinated coffee for lower dementia risk

• Evidence: A very long study (~40 years) found caffeinated coffee correlated with lower all-cause dementia risk.
• Decaf difference: Decaffeinated coffee did not show the same protective relationship.
• Dose guideline mentioned: Up to ~3 cups/day, linked to about a ~20% reduction in all-cause dementia.

Eat cheese without fear of increased dementia risk

• Evidence summary: Large-study and follow-up analyses found no increased dementia risk from cheese.
• Nuance:
  • Low-fat cheese: ~no relationship
  • High-fat cheese (noted as >50 g/day; high-fat defined with >20% dietary fat): slightly reduced risk
• Bottom line: Cheese (including high-fat types) appears neutral to beneficial for dementia risk.

Get lycopene mostly through tomato-based foods for plaque/cardiovascular support

• What was seen: Higher blood lycopene correlates with less arterial plaque deposition (inverse relationship).
• RCT detail: Only one direct RCT for lycopene supplementation was mentioned, showing plaque reversal.
• Long-term outcomes: Stronger evidence for cardiovascular benefit comes from foods (tomato products) rather than lycopene supplements alone.
• Practical target: 1 serving/day of tomato-based products (e.g., tomato paste/canned tomatoes) for supportive cardiovascular effects.
• Framing: Lycopene is likely part of a “whole package” of beneficial compounds in tomatoes.

---

Presenters / sources

• Presenter: The video speaker/author of the analysis (name not provided in the subtitles), discussing “Physiologic Insiders.”
• Sources referenced (by type, not individual names in subtitles):
  • Multiple randomized controlled trials
  • Meta-analysis on vitamin K2 and hepatocellular carcinoma
  • Several GLP-1 peptide clinical studies (example: semaglutide; also mentions tirzepatide and retatrutide)
  • Large cohort study on coffee and dementia (multi-decade duration)
  • Studies/analyses on cheese and dementia
  • Study(s) on lycopene and plaque reversal, plus longer-term cardiovascular outcome studies
  • Early-phase microbiome/cancer trials using microbiome modification (described as fecal transplant “pill”)